Compare PCRX & NMFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | NMFC |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 771.2M |
| IPO Year | 2010 | N/A |
| Metric | PCRX | NMFC |
|---|---|---|
| Price | $22.00 | $8.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 4 |
| Target Price | ★ $35.33 | $8.63 |
| AVG Volume (30 Days) | 739.7K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 15.80% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $9.77 | N/A |
| Revenue Next Year | $9.71 | N/A |
| P/E Ratio | $142.97 | ★ $12.51 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $7.52 |
| 52 Week High | $27.99 | $11.46 |
| Indicator | PCRX | NMFC |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 42.21 |
| Support Level | $20.41 | $7.91 |
| Resistance Level | $23.82 | $9.82 |
| Average True Range (ATR) | 1.00 | 0.25 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 43.41 | 52.25 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.